Three Chinese stocks double or surge, issue trading risk warnings after sharp rallies
On September 22, 2026, Mindong Electric, Nanhua Bio-medicine, and Aiai Precision issued trading risk warnings after extreme stock price surges. Mindong Electric's shares doubled in 10 trading days, with a static P/E of 158.91 versus the industry average of 18.62. The company stated its virtual power plant and offshore wind projects have no commercial revenue. Nanhua Bio, up 46.43% in four sessions, clarified it has no CRO business after terminating a planned acquisition in January 2026. Aiai Precision, up 156.45% since July, denied backdoor listing plans. All three warned of irrational speculation and potential sharp declines.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Speculation is a global phenomenon, not unique to China, and it often hurts ordinary investors the most.
- The companies involved issued warnings to investors, which is a responsible step toward transparency.
- High P/E ratios and stock surges disconnected from fundamentals are risky and unsustainable.
- Western media often applies a double standard, criticizing Chinese markets while excusing similar behavior in the West.
Points of contention
- Whether the stock surges reflect rational bets on future potential in strategic sectors or pure narrative-driven gambling.
- Whether Chinese investors are acting out of desperation due to limited economic options or exercising informed agency.
- Whether China's regulatory warnings are a sign of market maturity and investor protection or a tool for social stability.
- Whether the root cause is a systemic failure in the global economy or a specific issue with Chinese market conditions.
Blind spots
- Both sides focus on comparing China and the West, but neither deeply examines how to fix the underlying economic desperation that drives speculation everywhere.
- The debate overlooks the role of social media and online platforms in amplifying speculative manias across all markets.
- There is little discussion of concrete policy solutions, like better financial education or alternative investment options for ordinary people.
WorldAttention’s read
The roundtable shows broad agreement that speculative bubbles are a global issue, not a Chinese anomaly, and that company warnings are a positive step. However, deep disagreement remains on whether these stock surges are rational bets on future industries or desperate gambling, and whether China's regulatory approach is about protecting investors or maintaining social order. Both sides miss the bigger picture: ordinary people everywhere are chasing risky bets because the legitimate economy offers few good options. Until that root cause is addressed, bubbles and crashes will keep hurting the most vulnerable, no matter the market or the country.
Reporting timeline
Three Chinese Hot Stocks Issue Risk Warnings After Surges, Deny Rumors
On the evening of September 22, 2026, three Chinese listed companies—Mindong Electric Power, Nanhua Bio-medicine, and Aiai Precision—issued separate announcements warning of trading risks after sharp stock price surges. Mindong Electric Power, whose shares doubled in 10 trading days, stated it has not launched smart grid or green power direct-connection businesses, and its virtual power plant is in early stages with no commercial revenue. The company's static P/E ratio of 158.91 far exceeds the industry average of 18.62. Nanhua Bio-medicine, after four consecutive daily涨停 (limit-up) moves, clarified it has no CRO business following the termination of a planned acquisition of Huize Pharmaceutical in January 2026. Aiai Precision, which surged 156.45% since July 14, denied借壳上市 (backdoor listing) plans and stated its acquirer has no intention to inject assets or conduct business cooperation within 36 months. All three companies emphasized that their stock prices have deviated significantly from fundamentals and warned of potential rapid declines.
Read sourceThree Hot Stocks Issue Trading Risk Warnings After Sharp Price Surges
On the evening of September 22, 2026, three Chinese stocks—Mindong Electric (000993), Nanhua Bio (000504), and Aiai Precision (603580)—issued announcements warning of trading risks following extreme price movements. Mindong Electric's shares doubled in 10 trading days, with cumulative deviation reaching 100.02%. The company stated its fundamentals have not changed, its virtual power plant business is in early stages with no commercial revenue, and its offshore wind projects are not yet operational. It warned of non-rational speculation and potential sharp price declines. Nanhua Bio, after four consecutive涨停 (daily limit-up) sessions, clarified it has no CRO business after terminating a planned acquisition of Huize Pharma in January 2026. Aiai Precision, which surged 156.45% since July, denied plans for backdoor listing or business cooperation with its new controlling shareholder Shanghai Yusheng. All three companies emphasized that their stock prices have significantly deviated from fundamentals and warned of high valuation and rapid decline risks.
Read sourceMindong Electric, Nanhua Bio, Aiai Precision Issue Trading Risk Warnings After Sharp Stock Rallies
On the evening of September 22, 2026, three Chinese listed companies—Mindong Electric (000993), Nanhua Bio (000504), and Aiai Precision (603580)—issued announcements warning of trading risks after significant stock price surges. Mindong Electric's shares doubled in 10 trading days, with a cumulative deviation of 100.02%. The company stated it has not engaged in smart grid, computing-power synergy, or green electricity direct-connection businesses, and its virtual power plant business is in early incubation with no commercial revenue. Its static P/E ratio of 158.91 far exceeds the industry average of 18.62. Nanhua Bio, which rose 46.43% in four consecutive limit-up days, clarified it has no CRO business after terminating a planned acquisition of Huize Pharmaceutical in January 2026. Aiai Precision, which surged 156.45% since July 14, denied any plans for a backdoor listing or business cooperation with its new controlling shareholder Shanghai Yusheng, and stated it has no involvement in indium phosphide-related businesses. All three companies warned that their stock prices have deviated significantly from fundamentals and face high risks of sharp declines.
Read sourceShow 2 older updatesHide older updates
Chinese stocks surge then warn: Mindong, Nanhua, Aijin issue risk alerts
On September 22, 2026, three Chinese listed companies—Mindong Electric, Nanhua Bio-medicine, and Aijin Precision—issued stock trading risk warnings after sharp price increases. Mindong Electric's shares doubled in 10 trading days, reaching a price-to-earnings ratio of 547 times, far above the industry average of 20 times. The company clarified it has no operational 'virtual power plant' or 'smart grid' revenue and its offshore wind projects are not yet producing income. Nanhua Bio-medicine surged 46% in four consecutive涨停板 (daily limit-up moves), prompting the company to state it has no CRO business after terminating a planned acquisition of HuiZe Pharma in January 2026. Aijin Precision rose 156% since July, with the company denying any借壳上市 (backdoor listing) plans by its incoming controlling shareholder Shanghai Yusheng. All three companies warned that their stock prices have severely deviated from fundamentals and face high risk of rapid decline. The warnings come amid market speculation on new energy and biotech themes, despite weak underlying financial performance for some firms.
Read sourceMultiple Hot Stocks Issue Risk Warnings After Sharp Price Surges in China
On the evening of September 22, 2026, several Chinese hot stocks, including Mindong Electric (000993), Nanhua Bio-medicine (000504), and Aiai Precision (603580), issued announcements warning of trading risks after significant price surges. Mindong Electric's stock rose 100.02% in 10 trading days, far exceeding its industry peers, with a static P/E ratio of 158.91 versus the industry average of 18.62. The company stated its fundamentals have not changed, its virtual power plant business is in early stages with no revenue, and its offshore wind projects are not yet operational. Nanhua Bio-medicine, after four consecutive涨停 (daily limit up) sessions, clarified it has no CRO business after terminating a planned acquisition of Huize Pharmaceutical in January 2026. Aiai Precision, which saw its stock rise 156.45% since July 14, reiterated that its controlling shareholder has no plans for a backdoor listing or business cooperation in the next 36 months, and the company is not involved in indium phosphide-related businesses. All three companies warned of market sentiment overheating, irrational speculation, and potential sharp price declines.
Read source